World Vaccine Congress Europe 2022

October 11-14, 2022
Barcelona, Spain
Booth 79

What does it mean to be

INSIDE AFRICA ?

For us, it encompasses our local staff, decades of on-the-ground experience, strong working relationships with stakeholders of all types, cultural competence and a commitment to the region and its people. Because of this, we’re ready to respond at a moment’s notice to implement locally adapted and staffed studies in sub-Saharan Africa that produce high-quality research.
We have localized teams.
We are well-established.
We work with local partners.
We build sustainable local capacity.

We are responsive and adaptable.

We are ready at a moment’s notice.
We deliver high-quality research.

Visit us at WVC Europe to experience Africa

Visit booth 79 at World Vaccine Congress Europe to meet our team members and experience the sights, sounds and tastes of sub-Saharan Africa. We look forward to discussing how your next research project could benefit from the potential of and our experience in sub-Saharan Africa.

Sanchia Theron

Global Head, Medical Affairs

Ghiorghis (George) Belai
Vice President, Global Strategy
Karen Insley
Senior Account Development Manager,
Client Solutions

presentation

Oct 14, 2022 | 10:30 AM CEST

Tuberculosis (TB): The Silent “Pandemic” The World Has Forgotten

Presenter:  Sanchia Theron, Global Head, Medical Affairs
Location:  Level 2, Room 6
Tuberculosis (TB) is second only to COVID-19 among the infectious disease-related mortality rates worldwide. The need for effective, safe TB vaccines and treatments remains a global health priority, especially in the midst of increasing cases of multidrug-resistant TB (MDR-TB). In this presentation, Sanchia Theron will discuss the progress that the health and research community has made so far in addressing TB and reaching the goals of the End TB Strategy. Based on FHI Clinical’s experience with TB research, particularly in sub-Saharan Africa, the discussion will also include strategies to overcome research challenges presented by hard-to-reach populations, MDR-TB and established and emerging policies for TB preventive treatment (TPT).

Share this post